Vemurafenib resistance reprograms melanoma cells towards glutamine dependence

[1]  A. Ribas,et al.  Anti-PD-1 therapy in melanoma. , 2015, Seminars in oncology.

[2]  P. Queirolo,et al.  Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. , 2015, Cancer treatment reviews.

[3]  J. Larkin,et al.  Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. , 2015, Cancer cell.

[4]  P. Queirolo,et al.  BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies , 2015, OncoTargets and therapy.

[5]  J. Rasko,et al.  Targeting glutamine transport to suppress melanoma cell growth , 2014, International journal of cancer.

[6]  A. Ribas,et al.  Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. , 2014, The Lancet. Oncology.

[7]  Jason Li,et al.  Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. , 2014, Cancer discovery.

[8]  Dirk Schadendorf,et al.  Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. , 2014, The Lancet. Oncology.

[9]  A. Bucheit,et al.  Emerging insights into resistance to BRAF inhibitors in melanoma. , 2014, Biochemical pharmacology.

[10]  K. Thangavelu,et al.  Structural Basis for the Active Site Inhibition Mechanism of Human Kidney-Type Glutaminase (KGA) , 2014, Scientific Reports.

[11]  P. Ascierto,et al.  Association of CTLA-4 Polymorphisms with Improved Overall Survival in Melanoma Patients Treated with CTLA-4 Blockade: A Pilot Study , 2013, Cancer investigation.

[12]  John M. Asara,et al.  Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway , 2013, Nature.

[13]  C. Dang,et al.  Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. , 2012, Journal of medicinal chemistry.

[14]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[15]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[16]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[17]  Dirk Schadendorf,et al.  Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .

[18]  K. Thangavelu,et al.  Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism , 2012, Proceedings of the National Academy of Sciences.

[19]  Takashi Tsukamoto,et al.  Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. , 2012, Cell metabolism.

[20]  A. Ribas,et al.  Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. , 2011, Cancer research.

[21]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[22]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[23]  G. Riggins,et al.  Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. , 2010, Cancer research.

[24]  C. Thompson,et al.  Glutamine addiction: a new therapeutic target in cancer. , 2010, Trends in biochemical sciences.

[25]  Paul S Mischel,et al.  Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032 , 2010, Journal of Translational Medicine.

[26]  R. Deberardinis,et al.  Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer , 2010, Oncogene.

[27]  N. Curthoys,et al.  Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). , 2007, The Biochemical journal.

[28]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[29]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[30]  Antoni Ribas,et al.  Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. , 2014, Cancer discovery.

[31]  C. Reynolds,et al.  DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy. , 2005, Methods in molecular medicine.

[32]  F. Muggia,et al.  The rediscovery of DON (6-diazo-5-oxo-L-norleucine). , 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[33]  E. Casper,et al.  Phase I study of 6-diazo-5-oxo-L-norleucine (DON). , 1980, Cancer treatment reports.